《麻疹诊疗方案(2024年版)》解读

doi:10.19871/j.cnki.xfcrbzz.2024.05.019

摘要/Abstract

摘要： 麻疹是一种由麻疹病毒引起的、具有高度传染性的急性出疹性呼吸道传播疾病,主要症状包括发热、流涕、咳嗽、流泪、畏光和斑丘疹等。少数患者可并发肺炎、喉炎、中耳炎、心肌炎、脑炎等,重症感染可致死亡。尽管目前已大规模普及疫苗接种,但2022年全球仍有近136 000人死于麻疹,其中大部分是5岁以下的儿童。为进一步规范麻疹的临床诊疗工作,结合国内外研究进展和诊疗经验,国家卫生健康委员会发布了《麻疹诊疗指南(2024年版)》。本文通过综合相关研究进展对该指南进行了归纳与整理,内容涵盖了麻疹的病原学、流行病学、发病机制、病理变化、临床表现、并发症、实验室检查、诊断和鉴别诊断、治疗及预防等,以期增进对该指南的理解,旨在为临床医生防治麻疹提供依据和参考。

关键词: 麻疹, 麻疹病毒, 诊断, 治疗, 指南解读

Abstract: Measles is an acute exanthematous respiratory disease caused by the highly contagious measles virus. Its main symptoms include fever, runny nose, cough, watery eyes, photophobia, and maculopapular rash. A small number of patients may develop complications such as pneumonia, laryngitis, otitis media, myocarditis, encephalitis, and severe cases can be fatal. Despite the widespread availability of large-scale vaccination, nearly 136,000 people still died from measles in 2022, with the majority being children under the age of five. In order to further standardize the clinical diagnosis and treatment of measles, the National Health Commission has issued the Measles Diagnosis and Treatment Guidelines (2024 Edition) by integrating domestic and foreign research progress and clinical experience. This article summarizes and organizes the guidelines based on relevant research progress, covering the etiology, epidemiology, pathogenesis, pathological changes, clinical manifestations, laboratory tests, diagnosis and differential diagnosis, treatment, and prevention of measles, aiming to enhance understanding, improve practicality, and provide a basis and reference for clinicians in the prevention and treatment of measles.

Key words: Measles, Measles virus, Diagnosis, Treatment, Guideline interpretation

中图分类号:

R511.1

姚伟明, 林元龙, 冯世艳, 王福祥. 《麻疹诊疗方案(2024年版)》解读[J]. 新发传染病电子杂志, 2024, 9(5): 98-103.

Yao Weiming, Lin Yuanlong, Feng Shiyan, Wang Fuxiang. Interpretation of the Measles diagnosis and treatment guidelines (2024 Edition)[J]. Electronic Journal of Emerging Infectious Diseases, 2024, 9(5): 98-103.

参考文献

[1] STREBEL PM, ORENSTEIN WA.Measles[J]. N Engl J Med, 2019, 381(4):349-357.
[2] WORLD HEALTH ORGANIZATION.Measles[EB/OL].[2023-07-15].https://www.who.int/zh/news-room/fact-sheets/detail/measles.
[3] 中华人民共和国国家卫生与健康委员会. 麻疹诊疗方案(2024年版)[EB/OL]. http://www.nhc.gov.cn/ylyjs/pqt/202407/4662eb54f6f544338543bf053f9ce049/files/177eed168bd34a1c817af3b075e756e3.pdf.
[4] HÜBSCHEN JM, GOUANDJIKA-VASILACHE I, DINA J. Measles[J]. Lancet, 2022, 399(10325):678-690.
[5] LI X, GOODSON JL, PERRY RT.Measles Population Immunity Profiles:Updated Methods and Tools[J]. Vaccines (Basel), 2024, 12(8):937.
[6] DURRHEIM DN.Measles eradication-retreating is not an option[J]. Lancet Infect Dis, 2020, 20(6):e138-e141.
[7] O’CONNOR P, JANKOVIC D, MUSCAT M, et al. Measles and rubella elimination in the WHO Region for Europe:progress and challenges[J]. Clin Microbiol Infect, 2017, 23:504-510.
[8] LAKSONO BM, DE VRIES RD, DUPREX WP,et al.Measles pathogenesis, immune suppression and animal models[J]. Curr Opin Virol, 2020, 41:31-37.
[9] SCHENK J, ABRAMS S, THEETEN H, et al.Immunogenicity and persistence of trivalent measles, mumps, and rubella vaccines:a systematic review and meta-analysis[J]. Lancet Infect Dis, 2021, 21:286-295.
[10] PORTNOY A, JIT M, FERRARI M, et al.Estimates of case-fatality ratios of measles in low-income and middle-income countries:a systematic review and modelling analysis[J]. Lancet Glob Health, 2019, 7:e472-e481.
[11] ALLEN IV, MCQUAID S, PENALVA R, et al.Macrophages and dendritic cells are the predominant cells infected in measles in humans[J]. mSphere, 2018, 3:e00570-17.
[12] CATTANEO R, DONOHUE RC, GENEROUS AR, et al.Stronger together:multi-genome transmission of measles virus[J]. Virus Res, 2019, 265:74-79.
[13] 王禹,张玉林. 麻疹发病机制的研究进展[J]. 中华传染病杂志, 2022, 40(7):439-441.
[14] LAKSONO BM, FORTUGNO P, NIJMEIJER BM, et al.Measles skin rash:infection of lymphoid and myeloid cells in the dermis precedes viral dissemination to the epidermis[J]. PLoS Pathog, 2020, 16:e1008253.
[15] WILSON SE, SALVADORI MI, SCIENCE M.Measles[J]. CMAJ. 2024, 196(15):E524.
[16] LAKSONO BM, DE VRIES RD, VERBURGH RJ, et al.Studies into the mechanism of measles-associated immune suppression during a measles outbreak in the Netherlands[J]. Nat Commun, 2018, 9:4944.
[17] WRIGHT JR.Aldred Scott Warthin:Ann Arbor's Erudite, Outspoken, and Academically Transformative Early 20th Century Pathologist[J]. Arch Pathol Lab Med, 2021, 145(10):1297-1306.
[18] KIMURA H, SHIRABE K, TAKEDA M, et al.The association between documentation of Koplik spots and laboratory diagnosis of measles and other rash diseases in a national measles surveillance program in Japan[J]. Front Microbiol, 2019, 10:269.
[19] ANDREA LV, ANDRZE JK, CARLOTTA M, et al.Complications and risk factors for severe outcome in children with measles[J]. Arch Dis Child, 2020, 105(9):896-899.
[20] RAGUSA R, PLATANIA A, CUCCIA M, et al.Measles and pregnancy:immunity and immunization—what can be learned from observing complications during an epidemic year[J]. J Pregnancy, 2020, 6532868.
[21] CHARLIER C, DINA J, FREYMUTH F, et al.Prolonged maternal shedding and maternal-fetal transmission of measles virus[J]. Clin Infect Dis, 2021, 72:1631-1634.
[22] GARG RK, MAHADEVAN A, MALHOTRA HS, et al.Subacute sclerosing panencephalitis[J]. Rev Med Virol, 2019, 29(5):e2058.
[23] BROWN DW, WARRENER L, SCOBIE HM, et al.Rapid diagnostic tests to address challenges for global measles surveillance[J]. Curr Opin Virol, 2020, 41:77-84.
[24] ROTA PA, EVANS R, BEN MAMOU MC, et al.The Global Measles and Rubella Laboratory Network Supports High-Quality Surveillance[J]. Vaccines (Basel), 2024, 12(8):946.
[25] KUBA Y, NIDAIRA M, MAESHIRO N, et al.Analysis of suspected Measles cases with discrepant Measles-specific IgM and rRT-PCR test results, Japan[J]. Emerg Infect Dis, 2024, 30(5):926-933.
[26] DINA J, OMNES J, VAULOUP-FELLOUS C, et al.True measles cases undetected by reverse transcription-PCR (RT-PCR):effect of genetic variability on assay sensitivity needs to be regularly surveyed[J]. J Clin Microbiol, 2019, 57:e00341-19.
[27] WORLD HEALTH ORGANIZATION. Guide for clinical case management and infection prevention and control during a measles outbreak.2020[EB/OL]. https://apps.who.int/iris/handle/10665/331599.
[28] GEORGE MS, KHAN HR, KHADKA S, et al.Measles resurgence in Armenia:unmasking health system vulnerabilities and crafting comprehensive eradication strategies - a review[J]. Ann Med Surg (Lond). 2024, 86(9):5394-5400.
[29] WHO. Measles.In:Surveillance standards for vaccine-preventable diseases, 2nd edn. World Health Organization:Geneva, 2018[EB/OL].[2018-11-28]. https://www.who.int/immunization/monitoring_surveillance/burden/vpd/WHO_SurveillanceVaccinePreventable_11_Measles_BW_R2.pdf?ua=1.
[30] CONIS E.Measles and the modern history of vaccination[J]. Public Health Rep, 2019, 134:118-125.
[31] GRIFFIN DE.Measles Vaccine[J]. Viral Immunol, 2018, 31:86-95.
[32] DI PIETRANTONJ C, RIVETTI A, MARCHIONE P, et al. Vaccines for measles, mumps, rubella,varicella in children[J]. Cochrane Database Syst Rev, 2020, 4:CD004407.
[33] WORLD HEALTH ORGANIZATION. WHO immunological basis for immunization series:module 7:measles. Update2020[EB/OL].[2020-02-12]. https://apps.who.int/iris/bitstream/handle/10665/331533/9789241516655-eng.pdf?sequence=1&isAllowed=y.
[34] MATYSIAK-KLOSE D, SANTIBANEZ S, SCHWERDTFEGER C, et al.Post-exposure prophylaxis for measles with immunoglobulins revised recommendations of the standing committee on vaccination in Germany[J]. Vaccine, 2018, 36:7916-7922.
[35] DURRHEIM DN.Measles eradication—retreating is not an option[J]. Lancet Infect Dis, 2020, 20:e138-e141.